Elecoglipron
Sponsors
AstraZeneca AB, AstraZeneca
Conditions
Chronic Kidney DiseaseChronic kidney disease (CKD) in adultsHealthy ParticipantsHeart Failure With Mildly Reduced Ejection Fraction (HFmrEF)Heart Failure With Preserved Ejection Fraction (HFpEF)Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF);
on background SGLT2i.Nutritional, Metabolic, EndocrineObesity
Phase 1
Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
RecruitingNCT07662135
Start: 2026-07-06End: 2028-07-13Target: 900Updated: 2026-08-04
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
RecruitingNCT07662044
Start: 2026-07-06End: 2028-07-14Target: 800Updated: 2026-08-31
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
RecruitingNCT07662109
Start: 2026-07-06End: 2028-07-05Target: 2000Updated: 2026-08-31
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
RecruitingNCT07662213
Start: 2026-07-06End: 2028-05-23Target: 1200Updated: 2026-07-14
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
RecruitingNCT07664553
Start: 2026-07-08End: 2028-05-23Target: 600Updated: 2026-08-04
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
RecruitingNCT07667803
Start: 2026-06-29End: 2029-07-30Target: 4500Updated: 2026-07-10
A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)
Not yet recruitingCTIS2025-523933-24-00
Target: 110Updated: 2026-07-22
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)
Not yet recruitingCTIS2025-523994-41-00
Target: 260Updated: 2026-07-24
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)
Not yet recruitingCTIS2025-524688-19-00
Target: 325Updated: 2026-07-27
A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)
Not yet recruitingCTIS2026-526304-79-00
Target: 787Updated: 2026-07-30
A master protocol to investigate efficacy and safety of elecoglipron in participants with obesity or overweight with or without type 2 diabetes mellitus.
Active, not recruitingPACTR202607874630774
Start: 2026-09-14Target: 180Updated: 2026-08-03
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)
Not yet recruitingCTIS2025-523941-81-00
Target: 190Updated: 2026-08-05
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)
Not yet recruitingCTIS2025-523940-12-00
Target: 93Updated: 2026-08-05
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)
Not yet recruitingCTIS2025-523935-20-00
Target: 130Updated: 2026-08-04
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Not yet recruitingNCT07753993
Start: 2026-08-28End: 2030-10-04Target: 7000Updated: 2026-08-10
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Not yet recruitingNCT07761117
Start: 2026-08-28End: 2029-09-03Target: 6950Updated: 2026-08-12
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
RecruitingNCT07775404
Start: 2026-08-21End: 2028-04-20Target: 351Updated: 2026-08-27